echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Yuandong and Aosaikang grab the first imitation sword for children's medicine and target 5 billion large varieties

    Yuandong and Aosaikang grab the first imitation sword for children's medicine and target 5 billion large varieties

    • Last Update: 2022-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, a number of domestic star pharmaceutical companies have gathered together to produce esomeprazole magnesium enteric-coated dry suspension.
    Chengdu Yuandong Biotechnology submitted an application for 3 types of generic listing on November 29, Jiangsu Aosaikang Pharmaceutical|Yangzhou City Sanyao Pharmaceutical also submitted an application for 3 types of generic marketing today (December 1).
    This over 5 billion anti-peptic ulcer blockbuster children's dosage form has attracted market attention
    .
     
    Figure 1: The situation of companies that recently reported the production of esomeprazole magnesium enteric-coated dry suspension
    Source: CDE official website
     
    Figure 2: Sales Trend of Esomeprazole (Unit: Ten Thousand Yuan)
    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
    Esomeprazole is a single S isomer of omeprazole, and it is also the first drug with only one optical isomer among proton pump inhibitors.
    Compared with omeprazole and R-isomer, Esomeprazole has a low liver first-pass clearance effect, a slow intrinsic clearance rate, a high AUC value, a high and long-lasting active drug concentration in the plasma, and an enhanced effect on the proton pump and inhibition of gastric acid secretion
    .
    According to data from Meinnet.
    com, the sales of terminal esomeprazole in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) in 2020 will exceed 5 billion yuan, and will be treated in 2021H1 In the TOP list of peptic ulcer drugs , esomeprazole rose to third place, with a growth rate of up to 20%
    .
     
      At present, the best-selling dosage forms of esomeprazole on the domestic market include injections, enteric-coated tablets and enteric-coated capsules, and there is no enteric-coated dry suspension
    .
    Esomeprazole magnesium enteric-coated dry suspension is a child- specific proton pump inhibitor approved by the FDA .
    It has stable storage, accurate dosage, convenient administration, and good taste, which greatly improves the compliance of children.
    Sex
    .
     
      Table 1: Application status of esomeprazole magnesium enteric-coated dry suspension currently under review
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Beimei Pharmaceuticals and Cipla Pharmaceuticals of India signed an exclusive license agreement in China for esomeprazole magnesium enteric-coated dry suspension in October 2020, and the application for the import of imitation marketing was undertaken by CDE in April 2021.
    Currently under review and approval
    .
    Zhejiang Erying Pharmaceuticals | Zhejiang Jianfeng Pharmaceuticals, Shanghai Ambisheng Pharmaceutical Technology | Qingdao Baiyang Pharmaceuticals have submitted three types of generic listing applications in domestic pharmaceutical companies.
    After Osaikang and Yuandong entered the market, the domestic The dispute over the first imitation has become more fierce, and we will wait and see whether the imported imitation will be approved first or the domestic first imitation will appear first
    .
     
      In addition, it is worth noting that Esomeprazole Magnesium Enteric-coated Dry Suspension is expected to become Yuandong Bio's first drug in the field of anti-peptic ulcer
    .
     
      Source: CDE official website, Minet database
     
      Statistics are as of December 1.
    Please correct me if there are any errors or omissions
    .
      Recently, a number of domestic star pharmaceutical companies have gathered together to produce esomeprazole magnesium enteric-coated dry suspension.
    Chengdu Yuandong Biotechnology submitted an application for 3 types of generic listing on November 29, Jiangsu Aosaikang Pharmaceutical|Yangzhou City Sanyao Pharmaceutical also submitted an application for 3 types of generic marketing today (December 1).
    This over 5 billion anti-peptic ulcer blockbuster children's dosage form has attracted market attention
    .
     
      Figure 1: The situation of companies that recently reported the production of esomeprazole magnesium enteric-coated dry suspension
      Source: CDE official website
     
      Figure 2: Sales Trend of Esomeprazole (Unit: Ten Thousand Yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Esomeprazole is a single S isomer of omeprazole, and it is also the first drug with only one optical isomer among proton pump inhibitors.
    Compared with omeprazole and R-isomer, Esomeprazole has a low liver first-pass clearance effect, a slow intrinsic clearance rate, a high AUC value, a high and long-lasting active drug concentration in the plasma, and an enhanced effect on the proton pump and inhibition of gastric acid secretion
    .
    According to data from Meinnet.
    com, the sales of terminal esomeprazole in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) in 2020 will exceed 5 billion yuan, and will be treated in 2021H1 In the TOP list of peptic ulcer drugs , esomeprazole rose to third place, with a growth rate of up to 20%
    .
     
      At present, the best-selling dosage forms of esomeprazole on the domestic market include injections, enteric-coated tablets and enteric-coated capsules, and there is no enteric-coated dry suspension
    .
    Esomeprazole magnesium enteric-coated dry suspension is a child- specific proton pump inhibitor approved by the FDA .
    It has stable storage, accurate dosage, convenient administration, and good taste, which greatly improves the compliance of children.
    Sex
    .
     
      Table 1: Application status of esomeprazole magnesium enteric-coated dry suspension currently under review
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Beimei Pharmaceuticals and Cipla Pharmaceuticals of India signed an exclusive license agreement in China for esomeprazole magnesium enteric-coated dry suspension in October 2020, and the application for the import of imitation marketing was undertaken by CDE in April 2021.
    Currently under review and approval
    .
    Zhejiang Erying Pharmaceuticals | Zhejiang Jianfeng Pharmaceuticals, Shanghai Ambisheng Pharmaceutical Technology | Qingdao Baiyang Pharmaceuticals have submitted three types of generic listing applications in domestic pharmaceutical companies.
    After Osaikang and Yuandong entered the market, the domestic The dispute over the first imitation has become more fierce, and we will wait and see whether the imported imitation will be approved first or the domestic first imitation will appear first
    .
     
      In addition, it is worth noting that Esomeprazole Magnesium Enteric-coated Dry Suspension is expected to become Yuandong Bio's first drug in the field of anti-peptic ulcer
    .
     
      Source: CDE official website, Minet database
     
      Statistics are as of December 1.
    Please correct me if there are any errors or omissions
    .
      Recently, a number of domestic star pharmaceutical companies have gathered together to produce esomeprazole magnesium enteric-coated dry suspension.
    Chengdu Yuandong Biotechnology submitted an application for 3 types of generic listing on November 29, Jiangsu Aosaikang Pharmaceutical|Yangzhou City Sanyao Pharmaceutical also submitted an application for 3 types of generic marketing today (December 1).
    This over 5 billion anti-peptic ulcer blockbuster children's dosage form has attracted market attention
    .
     
      Figure 1: The situation of companies that recently reported the production of esomeprazole magnesium enteric-coated dry suspension
     
      Source: CDE official website
     
      Figure 2: Sales Trend of Esomeprazole (Unit: Ten Thousand Yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Esomeprazole is a single S isomer of omeprazole, and it is also the first drug with only one optical isomer among proton pump inhibitors.
    Compared with omeprazole and R-isomer, Esomeprazole has a low liver first-pass clearance effect, a slow intrinsic clearance rate, a high AUC value, a high and long-lasting active drug concentration in the plasma, and an enhanced effect on the proton pump and inhibition of gastric acid secretion
    .
    According to data from Meinnet.
    com, the sales of terminal esomeprazole in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) in 2020 will exceed 5 billion yuan, and will be treated in 2021H1 In the TOP list of peptic ulcer drugs , esomeprazole rose to third place, with a growth rate of up to 20%
    .
    Hospital hospital hospital medicine medicine medicine
     
      At present, the best-selling dosage forms of esomeprazole on the domestic market include injections, enteric-coated tablets and enteric-coated capsules, and there is no enteric-coated dry suspension
    .
    Esomeprazole magnesium enteric-coated dry suspension is a child- specific proton pump inhibitor approved by the FDA .
    It has stable storage, accurate dosage, convenient administration, and good taste, which greatly improves the compliance of children.
    Sex
    .
    Child, child, kid
     
      Table 1: Application status of esomeprazole magnesium enteric-coated dry suspension currently under review
     
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Beimei Pharmaceuticals and Cipla Pharmaceuticals of India signed an exclusive license agreement in China for esomeprazole magnesium enteric-coated dry suspension in October 2020, and the application for the import of imitation marketing was undertaken by CDE in April 2021.
    Currently under review and approval
    .
    Zhejiang Erying Pharmaceuticals | Zhejiang Jianfeng Pharmaceuticals, Shanghai Ambisheng Pharmaceutical Technology | Qingdao Baiyang Pharmaceuticals have submitted three types of generic listing applications in domestic pharmaceutical companies.
    After Osaikang and Yuandong entered the market, the domestic The dispute over the first imitation has become more fierce, and we will wait and see whether the imported imitation will be approved first or the domestic first imitation will appear first
    .
     
      In addition, it is worth noting that Esomeprazole Magnesium Enteric-coated Dry Suspension is expected to become Yuandong Bio's first drug in the field of anti-peptic ulcer
    .
     
      Source: CDE official website, Minet database
      
     
      Statistics are as of December 1.
    Please correct me if there are any errors or omissions
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.